Transgene's investigational new drug application for TG4010 in combination with nivolumab and chemotherapy as a first-line treatment for patients with lung cancer was approved by the FDA. A midstage trial that will evaluate the safety and tolerability of the drug, the objective tumor responses and disease control is expected to start by the end of the year in the US and Europe.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.